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Introduction
Prostacyclin (PGI2) is a member of the prostaglandin
family of lipid mediators. As with other prostaglan-
dins, PGI2 is a 20-carbon unsaturated carboxylic acid
with a cyclopentane ring. Prostacyclin, which is the
main product of arachidonic acid metabolism by
endothelial cells, has potent vasodilator and anti-
thrombotic activities.1,2
Characterization of the arachidonic acid cascade
has added considerable depth to our understanding of
processes that control vasodilatation and vasoconstric-
tion. Mediators with opposing actions such as the
vasodilator, anti-thrombotic substance prostacyclin
and the potent vasoconstrictor, platelet activator
substance thromboxane A2 (TXA2), exert their actions
locally and likely work in concert to maintain vascular
homeostasis.1,2 PGI2 deficiency has been implicated in
the pathogenesis of vascular diseases, e.g. peripheral
vascular disease.3 The development of new PGI2
analogs may allow more effective treatment of
vascular diseases. For example, critical limb ischemia
(CLI) is a collection of serious vascular diseases with
limited therapeutic options. CLI patients undergoing
standard therapy have a mortality rate of approxi-
mately 20% after 1 year, 40–70% after 5 years, and 95
and 80% after 10 years for patients presenting with
ischaemic gangrene and rest pain, respectively.4,5
Prostacyclin is a chemically unstable molecule, but
is available as a freeze-dried preparation (Epoproste-
nol) for intravenous administration to man. It is
supplied with an alkaline buffer, which allows the
solution to be infused for several hours. Gryglewski
and his colleagues in Krakow6 were the first to
demonstrate the beneficial effects of infusions of
prostacyclin in ischaemic disease of the legs. Szczeklik
et al.7 reported striking and prolonged benefits
following intra-arterial infusion of prostacyclin in
five patients with advanced atherosclerotic lower
limb peripheral vascular disease (PVD). Rest pain
disappeared, previously refractory ulcers healed and
the muscle blood flow, as measured by Xenon133
clearance, was significantly increased for at least 6
weeks after prostacyclin infusion. This group later
reported striking improvements in some of 55 patients
with advanced peripheral arterial disease of the lower
extremities.7
Other clinical trials followed, but the use of
prostacyclin has been limited by its instability and by
the need to infuse it intra-arterially. Several companies
have produced stable prostacyclin analogues, some
with oral activity: one (beraprost) is on the market in
Japan.8,9 The availability of a daily tablet that would
slow down or even prevent the atherosclerotic process
would make an enormous contribution to medicine.
A number of clinical studies over a 12-year period
involving 2000 patients with PVD demonstrated that
intravenous infusion of the stable prostacyclin analog
iloprost had a significant benefit compared to placebo
in terms of ulcer healing and rest pain at the end of
treatment (2–4 weeks) while amputation and death
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during the 6 months following treatment were also
significantly reduced.10 Although no clear success in
the treatment of CLI with oral iloprost has been
observed, i.e. short-term treatment but not long-term
treatment appeared beneficial,3 a non-intravenous
mode of prostacyclin analog treatment of CLI
is desirable. The prostacyclin analog remodulin
(UT-15),11 recently approved by the FDA for treatment
of primary pulmonary hypertension, is a stable
compound that is delivered by subcutaneous injection.
The development of new prostacyclin analogs with
greater potency might provide greater therapeutic
options. For instance, the stable analog UT-15 is 6-fold
more potent and 3-fold longer acting than iloprost in
studies of human pulmonary artery smooth muscle
cells.12 Thus, increasing our understanding of PGI2,
and its analogs, through study of its receptor and its
biosynthesis may contribute to the next major break-
through in vascular disease therapy. This article
reviews recent developments in these areas.
Review of Prostacyclin Synthesis
The synthesis of prostaglandins, including PGI2, is
initiated with the liberation of arachidonic acid from
membrane phospholipids by phospholipase A2.
1 In
addition, a phospholipase D pathway for the mobil-
ization of arachidonic acid from phospholipids of
endothelial cells has been described.15,16 These events
are followed by the oxidation of arachidonic acid to
hydroperoxy endoperoxide (PGG2) by cyclooxygen-
ase, and the subsequent reduction of PGG2 to hydroxy
endoperoxide (PGH2), again by cyclooxygenase.
1
Finally, the enzyme prostacyclin synthase converts
PGH2 to PGI2 (Fig. 1).
17,18
Following its synthesis and release, PGI2 exerts its
effects locally, is not stored, and is rapidly converted
by non-enzymatic processes to an inactive metabolite,
6-keto prostaglandin F1a (PGF1a).
1 PGI2 producing
cells located in the endothelium are sandwiched
between the two vascular target cells, the platelets on
the luminal side and vascular smooth muscle cells on
the basal side (Fig. 2).1
Prostacyclin Receptor
Cloning of the plasma membrane receptor
PGI2 was thought to operate through specific mem-
brane receptors based upon the observations that PGI2
agonists were able to elevate second messenger
levels19 and the detection of specific high affinity
Fig. 1. Pathway for prostacyclin synthesis. Arachadonic acid
is converted to prostaglandin G2 (PGG2) by cyclooxygenase.
PGG2 is then converted to prostaglandin H2 (PGH2) by the
action of cyclooxygenase. PGH2 is then converted to
prostacyclin (PGI2) by prostacyclin synthase.
Fig. 2. Relationship of prostacyclin producer and target cells
in the vasculature. Endothelial cells convert arachadonic
acid (AA) to prostacyclin (PGI2), which then leaves the
endothelial cells and interacts locally with the prostacyclin
receptor (IP) of blood platelets and arterial smooth muscle
eliciting antithrombotic and vasodilation responses,
respectively.
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surface binding sites for PGI2 agonists
20 in target
tissues. The cloning and expression of functional
plasma membrane prostacyclin receptor (IP) provided
unequivocal demonstration of a plasma membrane
signaling system for PGI2. IP is a member of the
prostanoid receptor subfamily, which in turn is a
member of the G protein coupled receptor (GPCR)
superfamily characterized by seven transmembrane
domains.21 The human thromboxane receptor (TP)
was cloned in 1991.22 The subfamily relationship of all
prostanoid receptors allowed homology screening for
IP based upon the TP sequence, and the cloning of the
human,23 – 25 mouse,26 and rat27 IP’s.
There were three reports of human IP cloning and
expression in 1994. In two separate studies cDNA
clones for functional human IP’s were isolated from a
lung cDNA library.23,24 The IP’s cloned from human
lung libraries were composed of 386 amino acids and
exhibited the putative seven transmembrane domains
characteristic of GPCR.23,24 Cloned IP’s were coupled
in that a stable PGI2 analog elicited a cAMP-dependent
response when the IP was expressed in Xenopus
oocytes23 and cAMP accumulation when expressed in
CHO cells.24 Radioreceptor assay on membranes from
COS23 or CHO24 cells transfected with the IP cDNA
displayed high affinity specific binding sites for PGI2.
Competition experiments with prostaglandins and
prostaglandin analogs exhibited the rank order of
potency expected for the IP.23,24 Cloning from a cDNA
library of CMK cells, a human megakaryocytic cell
line, also yielded similar results.25
Prostacyclin receptor gene structure
In the human genome, the IP gene is assigned to
chromosome 19 where it is present as a single copy,
spanning approximately 7 kb and composed of three
exons separated by two introns.28 The 50-flanking
region of the IP gene lacks TATA and CCAAT-like
boxes but contains several cis-acting regulatory
elements including glucocorticoid response elements,
AP-2 consensus sequences, AP-1 and SP-1 binding
sites, the human polyoma virus JC promoter, and
c-myb binding motifs.21,28 These regulatory elements
suggest a complex regulation of the IP gene where it
has features of constitutive and inducible genes.
Additionally, IP does not have splice variants as seen
with PGE1, PGE3, PGF, and TXA2 receptors.
21
Post-translational receptor modifications
Laboratory analyses of IP have revealed post-transla-
tional modifications, including, phosphorylation,29
isoprenylation,29,30 and glycosylation.31 The role of
receptor glycosylation in ligand binding or signal
transduction remains unclear.
An hIP expressed in the HEK293 cells exhibited a
basal level of phosphorylation that was protein kinase
C (PKC) dependent.29 Stimulation with agonist also
induced a PKC-dependent receptor phosphorylation.
Site-directed mutagenesis of the wild-type mIP
cysteine-414 residue to serine-414 established the
cysteine-414 residue as the site of isoprenylation. The
mutant receptor bound [3H] agonist and was noted to
have the same affinity and capacity as the wild-type
receptor. However, agonist did not cause cAMP
accumulation or [Caþ2]I mobilization as it did with
the wild-type receptor. Thus, isoprenylation was
required for efficient coupling of the receptor in the
system.
Agonist binding site
Prostaglandin receptors, including IP, recognize both
the cyclopentane ring and the side chains of prosta-
glandins. Studies based upon construction of chimeric
receptors32,33 and site-directed mutagenesis34
suggested a PGI2 binding pocket in the IP composed
of the first to second (ring recognition) transmembrane
domains and the seventh (side chain recognition)
transmembrane domain.
Coupling of receptors
Initial studies of the mechanism of PGI2 action
characterized it as an adenylate cyclase stimulating
agent.19 This mechanism was consistent with the
subsequent characterization of IP as a GPCR.21 As
with all G protein coupled receptors, the second
messenger systems activated by a receptor depend
upon the target cell.
Vascular smooth muscle presents a complex target
in that PGI2 actions may be a function of the cells
anatomical location. PGI2 inhibition of pulmonary
artery smooth muscle cell mitogenesis is greater with
distal derived cells as compared with proximal
derived cells.35 Furthermore, in the cerebral circulation
of the newborn pig, PGI2 was reported to have a
permissive action in the vasodilatory response to
hypercapnia.36 This action was suggested to work
through a phospholipase C and protein kinase C
dependent mechanism.36 In cultured preglomerular
vascular smooth muscle cells, PGI2 agonist does not
effect [Caþ2]I but is able to attenuate the angiotensin II
stimulated phospholipase C dependent increase of
[Caþ2]I.
37
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The vasorelaxant action of PGI2 is likely mediated
through cAMP,38 though there may be a cAMP-
independent coupling of the IP to activation of Kþ
channels that are key to relaxation of vascular smooth
muscle.39 Thus, cloned and expressed IP’s have the
capacity to couple to Gs as well as possibly other Ga
types.
Receptor desensitization and internalization
For a number of receptors phosphorylation of GPCR is
an important mechanism in the acute desensitization
of receptors to agonists.40 The hIP expressed in
HEK293 cells displayed a rapid, PGI2 agonist-
mediated PKC-dependent phosphorylation,29 as well
as an agonist-mediated desensitization of coupling to
adenylate cyclase.30 The kinetics of PGI2 agonist-
mediated desensitization of adenylate cyclase were
rapid, i.e. occurred in minutes.30 It was reported that
human fibroblasts expressing endogenous IP desensi-
tize adenylate cyclase coupling at rate that required
hours rather than minutes of agonist pretreatment.41
The discrepancy of these two reports may be
explained simply by the differences in the experimen-
tal conditions.
Human platelets preincubated in vitro with 0.1 mM
PGI2 agonist have demonstrated a time-dependent
desensitization to subsequent PGI2 agonist-stimulated
cAMP accumulation or inhibition of collagen induced
aggregation.42 The desensitization reflected the time-
dependent internalization of high affinity IP assayed
by [3H] PGI2 agonist binding. The in vitro platelet IP
desensitization was also shown to be reversible.43
Resensitization of cells has been observed following
withdrawal of PGI2 agonist, however, the time to
resensitization may be related to the dose of PGI2
agonist used in the desensitization process.43 This
dose-related response may have important clinical
implications for the use of PGI2 or its analogs in the
treatment of patients with vascular diseases. For
instance, although the synthetic PGI2 agonists share
similar general features, e.g. stimulation of adenylate
cyclase, they exhibit significantly different behaviors
in terms of kinetics, potency, and possibly desensitiza-
tion of their actions. Desensitization has also been
observed with other vasoactive mediator agonists
including IP mediated TP desensitization.44
Vascular smooth muscle cell proliferation and
desensitization may play an important role in the
pathogenesis of vascular disease as well as its
treatment with PGI2 or its analogs.
45 In a recent
publication, the in vitro PGI2 mediated inhibition of
vascular smooth muscle cell mitogenesis was
described.46 The antimitogenic action of PGI2 may be
important to vascular homeostasis, although this
action has yet to be clearly demonstrated in vivo. It
is thus interesting that smooth muscle cells in vitro
were shown to be desensitized to the antimitogenic
actions of PGI2 agonist.
47 It was suggested that
desensitization occurred at the level of the IP since
the cells were not desensitized to the antimitogenic
effects of either PGE1 or forskolin.
47
Since one mechanism of desensitization is uncou-
pling of receptors it may be relevant that Ruan et al.48
demonstrated impaired coupling of IP from Gs in
preglomerular arterioles from spontaneously hyper-
tensive rats as compared to age-matched normoten-
sive animals. The uncoupling of the spontaneously
hypersensitive rat IP might reflect a desensitization
phenomenon.
The internalization of membrane receptors rep-
resents a second mechanism that may lead to a
decrease in the response of target cells to an agonist.
In a study by Smyth, HEK293 cells expressing the hIP
exhibited time- and dose-dependent IP loss from the
cell surface suggestive of receptor internalization.49
PGI2 Synthesis
Phospholipase A2, cyclooxygenase, and PGI2 synthase
(PGIS) are the principal enzymes for the synthesis of
PGI2.
50 Immunoelectron microscopy of human mono-
cytes, human umbilical vein endothelial cells, and
NIH3T3 cells revealed COX-1 and COX-2 to be
localized to the luminal surface of the endoplasmic
reticulum and nuclear envelope.51 Immunofluorescent
confocal microscopy also demonstrated the co-local-
ization of COX-1 and PGIS to the endoplasmic
reticulum and nuclear envelope of cultured bovine
aortic endothelial cells.52 In CHO cells, the Caþ2
ionophore A23187 was found to induce translocation
of cytosolic phospholipase A2 to endoplasmic reticu-
lum and nuclear envelope but not to plasma mem-
branes.53 The enzyme in both locations was functional
and was found to catalyze the liberation of arachidonic
acid from phospholipids.53
Enzyme localization to the nuclear envelope of
endothelial cells is an intriguing observation and leads
one to wonder why a cell makes PGI2 at the nucleus?
One possible explanation would be a nuclear site of
action for PGI2 in the producer cell.
54 – 59
The ability of endothelial cells to synthesize PGI2
from prostaglandin endoperoxides generated by acti-
vated platelets was first proposed by Bunting et al.61 in
the mid-1970s. This transcellular pathway for PGI2
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synthesis was subsequently demonstrated in vitro62
and in vivo.63
Activated platelets have been shown to actively
shed microparticles.64 Arachidonic acid in platelet
microparticles has been demonstrated to upregulate in
vitro COX-2 and prostacyclin production by endo-
thelial cells through a PKC and mitogen activated
protein kinase dependent pathway.65 Thus, activated
platelets may enhance endothelial PGI2 production by
two mechanisms: the supply of prostaglandin endo-
peroxides results in a rapid increase of PGI2 synthesis
and the slower upregulation of COX-2 may maintain
increased PGI2 production.
Endothelial cells are exposed to fluid flow or shear
stress in vivo. The ability of the endothelial cells to
detect shear stress and respond to its changes is
important to vascular homeostasis. An increase in
shear stress was noted to upregulate PGI2 production
by endothelial cells in a biphasic manner.67 – 69 Shear
stress has also been shown to upregulate mRNA levels
for COX-1, COX-2, and PGIS in cultured human
endothelial cells.70 Cross talk of shear stress-induced
PGI2 and nitric oxide has also been described for
cultured endothelial cells.71
Inhibitors of nitric oxide synthase and guanylate
cyclase both increased the flow enhanced PGI2
production in vitro but had no effect under static
conditions.71 PGI2 is not thought to play as important
role as nitric oxide in systemic regulation of blood
pressure.72,73 However, it may play an important
compensatory role with failure of nitric oxide pro-
duction. Disruption of shear stress-induced regulation
of PGI2 may be important to vascular pathology.
Turbulent shear stress, unlike the more physiological
laminar shear, does not upregulate COX-2 and PGI2
expression.74 It has been suggested that turbulent
shear stress might resemble flow experienced by
endothelial cells at sites of atherogenic lesions.65,74
Animal Studies
IP-deficient knockout mice
IP-deficient knockout mice were developed by Murata
and colleagues in 1997.73 The mice were normotensive,
which provides strong evidence that PGI2 does not
play a central role in regulation of vascular homeo-
stasis in the systemic circulation. Rather, its role is
probably to work on demand in response to local
stimuli, e.g. prevention of vasospasm and thrombosis
in response to TXA2.
A stable PGI2 analog inhibited ADP-induced
aggregation of wild-type platelets in vitro. However,
no inhibition of ADP-induced platelet aggregation
was observed in studies performed in IP-deficient
mice. Likewise, in vitro studies revealed that PGI2
agonist was able to relax noradrenaline-constricted
aortic rings of wild-type mice but was not able to in the
IP-deficient mice.
The in vivo studies have revealed an inability of
intravenous PGI2 agonist to transiently reduce blood
pressure in IP-deficient mice as it did in the normal
animals. In addition, an enhanced thrombotic ten-
dency upon endothelial damage (from topically
applied FeCl3 to carotid arteries) was noted in IP-
deficient animals as compared to wild-type controls.
Transgenic mice overexpressing prostacyclin synthase
Pulmonary-specific overexpression of the PGI2
synthase in the respiratory epithelium of transgenic
mice was reported.75 This was accomplished with a
transgene construct of the human SP-C promoter (that
directs pulmonary-specific gene expression) with the
rat PGI2 synthase gene. Homogenates of lung tissue
from PGI2 synthase overexpressing animals exhibited
a 2-fold increase in ability to transform arachidonic
acid to 6-keto PGF1a. The transgenic animals were
protected from hypoxic pulmonary hypertension as
compared to non-transgenic littermates. Transepithe-
lial delivery of PGI2 to pulmonary vasculature was
considered responsible for this effect, although the
precise mechanism remains unknown.
Cell-based gene transfer
A replication defective adenovirus expression vector
carrying the human COX-1 gene was employed to
transfect balloon injured porcine carotid arteries in
vivo.76 Enhanced production of PGI2 due to trans-
fected COX-1 was associated with prevention of
angioplasty-induced thrombosis and cyclic flow
changes.
It has also been demonstrated that the PGI2
synthase gene can be directly transfected in vivo into
the balloon-injured carotid arteries of rats.77,78 Both
studies employed non-viral liposome methods of gene
transfer and similar results were obtained employing
the rat77 or the human78 PGI2 synthase gene. Elevated
production of PGI2 in the carotid arterial wall was
noted and neointima formation was inhibited.
Early responses to balloon injury are initiated by
thrombus formation with subsequent production of
growth factors that stimulate smooth muscle cell
migration from media to intima, smooth muscle cell
growth, and smooth muscle cell production of
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extracellular matrix.43 Elevation of endogenous PGI2
production might have one or more sites of action
since PGI2 can antagonize events from platelet
aggregation13,79 to smooth muscle cell proliferation.35
Clinical Significance
Currently, stable PGI2 analogs are used clinically in the
treatment of patients with PVDs. Our rapidly expand-
ing understanding of the basic biology of this
important vasoactive mediator as well as the contribu-
tory role of other paracrines in maintaining vascular
homeostasis is likely to increase the clinical role of
these agents. The successful clinical use of PGI2
analogs to treat vascular disease can be increased by
consideration of the basic biology of PGI2 described in
this review.
First, the cloning of the IP and subsequent detailed
analysis of ligand receptor interactions and coupling
mechanisms may play a critical role in the develop-
ment of increasingly selective agonists or antagonists.
For example, in vitro studies of the clinically employed
PGI2 analogs iloprost and remodulin have shown that
at optimal doses for each that remodulin elicits a 6-fold
greater cAMP response than iloprost, that persists for
at least three times longer in human arterial smooth
muscle cells.12 Thus, it is reasonable to project that
these two analogs may have different clinical efficacies,
depending upon the target tissue.
A second area, that has received little clinical
attention, is the role of desensitization to PGI2 in
PGI2 analog therapy. It is well established that tissues
may become refractory to agonists through receptor
mediated mechanisms, and in vitro studies have
demonstrated this phenomenon for PGI2 and its
analogs.40 – 43 The clinical efficacy of PGI2 therapy
might be seriously impacted by the desensitization
response to the treatment agent. It was reported that
short term (4 weeks) but not long term (52 weeks) oral
iloprost treatment was beneficial to CLI patients.3
Although there are a number of possible explanations
for this somewhat paradoxical observation, the lack of
efficacy for long-term PGI2 analog therapy might
represent a desensitization effect, i.e. with long-term
treatment target tissues desensitized to analog and
endogenous PGI2 and beneficial effects of the analog
therapy were lost. Considering the reversibility of in
vitro desensitization, the clinician might someday
employ a desensitization index to guide dosing with
PGI2 analogs. Since human platelets desensitize to
PGI2 analogs in vitro, blood could be drawn from
patients periodically and the inhibition of induced
platelet aggregation by PGI2 analogs monitored as an
index of desensitization. Patients could then be
cycled on and off drugs, guided by the state of
desensitization.
Finally, it is likely that the experimental demon-
stration of transgene therapy to enhance endogenous
PGI2 production and successfully treat vascular
damage may have clinical applications in the future.80
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